Benjamin J. Zeskind, President and CEO at Immuneering, bought IMRX on Jun 23, 2026
Data as of Oct 27
- Traded
- Jun 23, 2026
- Disclosed
- Jun 24, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
IMRX since disclosure
−16.7%
Similar stocks (XLV) since disclosure
+16.8%
XLV — its sector index fund
Change in closing price from Jun 24, 2026 (the first trading day on or after disclosure) to Oct 27, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.